The 15 most recent market catalysts affecting $NTLA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 12, 2026
Corporate Catalyst
Bullish
Impact 85
Intellia Therapeutics Presents Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran at ACAAI 2026
Intellia Therapeutics announced compelling data for lonvoguran ziclumeran from its HAELO Phase 3 trial and earlier studies. The drug demonstrated an 81% decrease in monthly attack …
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 55
J.P. Morgan Adjusts Price Target for Intellia Therapeutics
J.P. Morgan analyst Brian Cheng has maintained a 'Sell' rating on Intellia Therapeutics (NTLA), while simultaneously increasing the price target from $8 to $9. This action signals …
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 95
Intellia Therapeutics Announces Third Quarter 2026 Financial Results
Intellia Therapeutics has released its third-quarter 2026 financial results and business updates. This is a routine but highly impactful event for publicly traded companies, as it …
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 75
Intellia Therapeutics and Regeneron Complete Enrollment in Phase 3 Trial of nex-z
Intellia Therapeutics and Regeneron Pharmaceuticals announced the completion of patient enrollment in their Phase 3 MAGNITUDE-2 clinical trial for nex-z. This is a significant oper…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 65
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial
Intellia Therapeutics has completed enrollment for its Phase 3 MAGNITUDE-2 trial of nexiguran ziclumeran, a CRISPR-based gene-editing therapy for ATTRv-PN. This is a crucial operat…
Nov 3, 2026
Corporate Catalyst
Neutral
Impact 75
Intellia Therapeutics Announces Upcoming Clinical Data Presentations for Nexiguran Ziclumeran
Intellia Therapeutics is announcing upcoming presentations of clinical data for its drug nexiguran ziclumeran at two significant medical conferences: AHA and ISA. This matters beca…
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 65
Intellia Therapeutics Announces Upcoming Investor Event and ACAAI Presentations
Intellia Therapeutics is disclosing plans for an investor event and multiple presentations at a significant medical conference in 2026. The key takeaway is the upcoming release of …
Oct 24, 2026
Corporate Catalyst
Bullish
Impact 65
NeuroThera Labs Reports Progress in Phase IIb Clinical Trial for Tourette Syndrome
NeuroThera Labs has announced a critical operational milestone for its Phase IIb clinical trial of SCI-110 for Tourette Syndrome. The completion of manufacturing and securing batch…
Oct 6, 2026
Corporate Catalyst
Neutral
Impact 65
Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8
Barclays analyst Gena Wang initiated coverage on Intellia Therapeutics (NTLA) with an 'Underweight' rating and an $8 price target. This is a significant event for NTLA as new analy…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Buy' rating on Intellia Therapeutics (NTLA) and maintained a $25 price target. This action signifies that the analy…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Intellia Therapeutics Announces FDA Acceptance For Its Biologics License Application For Ionvo-Z; FDA Sets March 10, 2027, As PDUFA Date
Intellia Therapeutics (NTLA) announced a major regulatory milestone: the FDA has accepted its Biologics License Application (BLA) for Ionvo-Z and granted it Priority Review. This i…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 65
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24
Evercore ISI Group's upgrade of Intellia Therapeutics (NTLA) to Outperform, coupled with a significant price target increase from $16 to $24, indicates a more bullish outlook from …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Intellia Therapeutics Q2 EPS $(0.80) Misses $(0.79) Estimate, Sales $7.659M Miss $13.904M Estimate
Intellia Therapeutics (NTLA) announced Q2 results that fell short of analyst expectations on both the top and bottom lines. The company reported a loss of $(0.80) per share, slight…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 75
Intellia Therapeutics shares are trading lower after Wolfe Research downgraded the stock from Peer Perform to Underperform rating and announced a $9 price target.
The downgrade of Intellia Therapeutics by Wolfe Research from 'Peer Perform' to 'Underperform' with a significantly lower price target of $9 is a strong negative signal for the com…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 75
Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target
Wolfe Research's downgrade of Intellia Therapeutics (NTLA) to Underperform with a $9 price target is a significant event for the company. Analyst downgrades from reputable firms li…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.